Floatz logo

Sodium Thiosulfate

Ototoxicity

Children's Oncology GroupSmall moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Ototoxicity cohort.

Asset / SponsorPhaseRating
D-thioctic acid
US Department of Veterans Affairs
Phase 2/3B
Spi-1005 Ebselen
Sound Pharmaceuticals, Incorporated
Phase 2B
Cholesterol Suspension
University of Colorado, Denver
Phase 2NR

Same molecule, other indications

Sodium Thiosulfate is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
sarcomaDormant
BB
Indicative ·
65 / 100
View asset →
Epithelial Ovarian CancerDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →